Sorafenib Inhibits Lymphoma Xenografts by Targeting MAPK/ERK and AKT Pathways in Tumor and Vascular Cells

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Carlo Stella, Carmelo ^a,b   Locatelli, Silvia L ^a,b   Giacomini, Arianna ^a,b   Cleris, Loredana ^c   Saba, Elena ^b   Righi, Marco ^d   Guidetti, Anna ^b,c   Gianni, Alessandro M ^b,c  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SORAFENIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOMA; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; TUMOR CELL; TUMOR VOLUME; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; CELL COUNT; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ENDOTHELIAL CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; LYMPHOMA; MAP KINASE SIGNALING SYSTEM; MICE; MICE, SCID; NECROSIS; NEOVASCULARIZATION, PATHOLOGIC; NIACINAMIDE; PERICYTES; PHENYLUREA COMPOUNDS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84876448099     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061603     Document Type: Article

References (41)

1. Kane RC, Farrell AT, Saber H, Tang S, Williams G, et al. (2006) Sorafenib for the treatment of advanced renal cell carcinoma. Clinical Cancer Research 12: 7271-7278.
2. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, et al. (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. The New England Journal of Medicine 356: 125-134.
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390.
4. Clark JW, Eder JP, Ryan D, Lathia C, Lenz HJ, (2005) Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clinical Cancer Research 11: 5472-5480.
5. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, et al. (2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. Journal of Clinical Oncology 23: 965-972.
6. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, et al. (2008) Phase II trial of sorafenib in advanced thyroid cancer. Journal of Clinical Oncology 26: 4714-4719.
7. Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, et al. (2008) Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. Journal of National Cancer Institute 100: 184-198.
8. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, et al. (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nature Reviews Drug Discovery 5: 835-844.
9. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, et al. (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Molecular Cancer Therapeutics 7: 3129-3140.
10. Fabian MA, Biggs WH 3rd, Treiber DK, Atteridge CE, Azimioara MD, et al. (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nature Biotechnology 23: 329-336.
11. Roberts PJ, Der CJ, (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26: 3291-3310.
12. Rahmani M, Davis EM, Bauer C, Dent P, Grant S, (2005) Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. Journal of Biology Chemistry 280: 35217-35227.
13. Meng XW, Lee SH, Dai H, Loegering D, Yu C, et al. (2007) Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. Journal of Biological Chemistry 282: 29831-29846.
14. Yu C, Bruzek LM, Meng XW, Gores GJ, Carter CA, et al. (2005) The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 24: 6861-6869.
15. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, et al. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Research 64: 7099-7109.
16. Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD, et al. (2005) Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Research 65: 2412-2421.
17. Chang YS, Adnane J, Trail PA, Levy J, Henderson A, et al. (2007) Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemotherapy and Pharmacology 59: 561-574.
18. Liu L, Cao Y, Chen C, Zhang X, McNabola A, et al. (2006) Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Research 66: 11851-11858.
19. Nguyen TK, Jordan N, Friedberg J, Fisher RI, Dent P, et al. (2010) Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis. Leukemia Research pp. 379-386.
20. Chapuy B, Schuelper N, Panse M, Dohm A, Hand E, et al. (2011) Multikinase inhibitor sorafenib exerts cytocidal efficacy against Non-Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation. British Journal of Haematology 152: 401-412.
21. Ullrich K, Wurster KD, Lamprecht B, Kochert K, Engert A, et al. (2011) BAY 43-9006/Sorafenib blocks CSF1R activity and induces apoptosis in various classical Hodgkin lymphoma cell lines. Br J Haematol 155: 398-402.
22. Ramakrishnan V, Timm M, Haug JL, Kimlinger TK, Halling T, et al. (2012) Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin. Am J Hematol 87: 277-283.
23. Huber S, Oelsner M, Decker T, Zum Buschenfelde CM, Wagner M, et al. (2011) Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1. Leukemia 25: 838-847.
24. Minn AJ, Rudin CM, Boise LH, Thompson CB, (1995) Expression of bcl-xL can confer a multidrug resistance phenotype. Blood 86: 1903-1910.
25. Jazirehi AR, Vega MI, Chatterjee D, Goodglick L, Bonavida B, (2004) Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab. Cancer Research 64: 7117-7126.
26. Cho-Vega JH, Rassidakis GZ, Admirand JH, Oyarzo M, Ramalingam P, et al. (2004) MCL-1 expression in B-cell non-Hodgkin's lymphomas. Human Pathology 35: 1095-1100.
27. Lavazza C, Carlo-Stella C, Giacomini A, Cleris L, Righi M, et al. (2010) Human CD34+ cells engineered to express membrane-bound tumor necrosis factor-related apoptosis-inducing ligand target both tumor cells and tumor vasculature. Blood 115: 2231-2240.
28. Carlo-Stella C, Di Nicola M, Turco MC, Cleris L, Lavazza C, et al. (2006) The anti-human leukocyte antigen-DR monoclonal antibody 1D09C3 activates the mitochondrial cell death pathway and exerts a potent antitumor activity in lymphoma-bearing nonobese diabetic/severe combined immunodeficient mice. Cancer Research 66: 1799-1808.
29. Rybak JN, Ettorre A, Kaissling B, Giavazzi R, Neri D, et al. (2005) In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature. Nature Methods 2: 291-298.
30. Hu S, Niu H, Inaba H, Orwick S, Rose C, et al. (2011) Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. Journal of the National Cancer Institute 103: 893-905.
31. Gratzinger D, Zhao S, Marinelli RJ, Kapp AV, Tibshirani R, et al. (2007) Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large B-cell lymphoma subtypes. American Journal of Pathology 170: 1362-1369.
32. Righi M, Giacomini A, Lavazza C, Sia D, Carlo-Stella C, et al. (2009) A computational approach to compare microvessel distributions in tumors following antiangiogenic treatments. Laboratory Investigation 89: 1063-1070.
33. Bottos A, Martini M, Di Nicolantonio F, Comunanza V, Maione F, et al. (2012) Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia. Proc Natl Acad Sci U S A 109: E353-359.
34. Liu LP, Ho RL, Chen GG, Lai PB, (2012) Sorafenib inhibits hypoxia-inducible factor-1alpha synthesis: implications for antiangiogenic activity in hepatocellular carcinoma. Clin Cancer Res 18: 5662-5671.
35. Guidetti A, Carlo-Stella C, Locatelli SL, Malorni W, Pierdominici M, et al. (2012) Phase II study of sorafenib in patients with relapsed or refractory lymphoma. Br J Haematol 158: 108-119.
36. Jain RK, (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62.
37. Carmeliet P, Jain RK, (2011) Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 10: 417-427.
38. Bergers G, Song S, (2005) The role of pericytes in blood-vessel formation and maintenance. Neuro Oncol 7: 452-464.
39. Grant S, (2008) Cotargeting survival signaling pathways in cancer. Journal of Clinical Investigation pp. 4.
40. Ganjoo K, Moore A, Orazi A, Sen J, Johnson C, et al. (2008) The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: a retrospective study of 97 patients. Journal of Cancer Research and Clinical Oncology 134: 381-387.
41. Gratzinger D, Zhao S, Tibshirani R, Hsi E, Hans C, et al. (2008) Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy. Laboratory Investigation 88: 38-47.